PHILIP MALINAS: Open Payments
NPI 1700934825 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$16,680 in 159 payments from 17 companies in 2025. Trend: 2023 $9,858 · 2024 $11,621 · 2025 $16,680
Speaker / faculty: $11,772Food & beverage: $3,216Travel & lodging: $1,133Consulting: $560
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $14,033 |
| ABBVIE INC. | 27 | $478 |
| Neurocrine BioSciences, Inc. | 10 | $337 |
| E.R. Squibb & Sons, L.L.C. | 12 | $296 |
| Vanda Pharmaceuticals Inc. | 15 | $263 |
| Otsuka America Pharmaceutical, Inc. | 10 | $224 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $217 |
| Collegium Pharmaceutical, Inc. | 21 | $201 |
| Tris Pharma Inc | 9 | $172 |
| Alkermes, Inc. | 7 | $159 |
Products named: AUSTEDO XR, VRAYLAR, INGREZZA, COBENFY, CAPLYTA, Jornay PM, FANAPT, Dyanavel XR.
Industry payments across NV — which companies pay providers there.
